Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJul 11, 2026
DataAggregated Company Financials
Companies20
  • 7D-1.2%
  • 3M26.0%
  • 1Y-22.2%
  • YTD-4.5%

Over the last 7 days, the Healthcare industry has dropped 1.2%, driven by a pullback from Novo Nordisk of 1.4%. The industry has fallen 22% in the last year. Earnings are forecast to grow by 1.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 11 Jul 2026DKK 1.9tDKK 469.2bDKK 147.1b20.6x12.6x4x
Mon, 08 Jun 2026DKK 1.7tDKK 468.9bDKK 147.1b19.7x11.4x3.6x
Wed, 06 May 2026DKK 1.7tDKK 447.8bDKK 130.1b18.2x12.9x3.8x
Fri, 03 Apr 2026DKK 1.5tDKK 447.8bDKK 130.0b17.4x11.3x3.3x
Sun, 01 Mar 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.4x3.3x
Tue, 27 Jan 2026DKK 2.3tDKK 453.4bDKK 136.7b18.6x16.5x5x
Thu, 25 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Sat, 22 Nov 2025DKK 1.9tDKK 454.4bDKK 137.1b17.1x13.5x4.1x
Mon, 20 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Wed, 17 Sep 2025DKK 2.1tDKK 447.0bDKK 141.6b19.1x14.7x4.7x
Fri, 15 Aug 2025DKK 1.9tDKK 444.6bDKK 140.3b27.8x13.5x4.3x
Sun, 13 Jul 2025DKK 2.4tDKK 423.1bDKK 124.5b29.9x19.3x5.7x
Tue, 10 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Thu, 08 May 2025DKK 2.4tDKK 422.7bDKK 124.7b22x19.5x5.7x
Sat, 05 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Mon, 03 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Wed, 29 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29x29.9x8.6x
Fri, 27 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.8x29.5x8.5x
Sun, 24 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35x10.1x
Tue, 22 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.6x38.9x11.2x
Thu, 19 Sep 2024DKK 4.5tDKK 371.9bDKK 107.1b36.1x42.2x12.2x
Sat, 17 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Mon, 15 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Wed, 12 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.7x46.3x13.9x
Fri, 10 May 2024DKK 4.5tDKK 355.3bDKK 106.5b34.6x42.3x12.7x
Sun, 07 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.7x13x
Tue, 05 Mar 2024DKK 4.5tDKK 340.0bDKK 98.9b38x45.6x13.3x
Thu, 01 Feb 2024DKK 4.0tDKK 320.8bDKK 90.1b31.8x44.2x12.4x
Sat, 30 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Mon, 27 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Wed, 25 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.6x42.9x11.5x
Fri, 22 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b34.4x41.4x11.1x
Sun, 20 Aug 2023DKK 3.3tDKK 303.2bDKK 81.2b36.8x40.8x10.9x
Tue, 18 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39.3x38.9x10.2x
Price to Earnings Ratio

38.9x


Total Market Cap: DKK 2.9tTotal Earnings: DKK 75.4bTotal Revenue: DKK 286.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 29.1x.
  • The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.44%
Healthcare-1.24%
Life Sciences3.96%
Medical Equipment-0.23%
Biotech-1.31%
Pharma-1.39%
Healthtech-3.30%
Healthcare Services-6.69%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.9x.
    • Analysts are expecting annual earnings growth of 20.1%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.2% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 401.001.5%
+DKK 1.4b		-33.2%PE42.9x
AMBU B AmbuDKK 68.602.9%
+DKK 514.5m		-28.7%PE37.9x
GUBRA GubraDKK 355.608.4%
+DKK 450.8m		-14.3%PE3.4x
CHEMM ChemoMetecDKK 409.800.6%
+DKK 41.8m		-23.8%PE40.3x

Latest News

ZEAL
DKK 282.00
Zealand Pharma
7D
-6.6%
1Y
-23.0%
Narrative Update • Jul 09

ZEAL: Obesity Program Execution Will Support Future Upside Beyond Reset Expectations

Analysts have trimmed their average price target for Zealand Pharma to DKK 300, down sharply from previous levels. They cite more cautious peak sales expectations for petrelintide and survodutide, along with a view that potential upside may take longer to materialise.
EMBLA
DKK 26.25
Embla Medical hf
7D
-2.4%
1Y
-19.2%
Narrative Update • Jul 09

EMBLA: Buybacks And Tighter Assumptions Will Shape Measured Future Upside Potential

Analysts have reduced their price target for Embla Medical hf. from DKK 34.0 to DKK 29.0, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple.
DEMANT
DKK 272.20
Demant
7D
-3.4%
1Y
3.3%
Narrative Update • Jul 07

DEMANT: Hearing Market Turnaround And Sector Inflection Shape Balanced Outlook

Analysts have adjusted the fair value estimate for Demant to DKK 300 from DKK 316, reflecting updated assumptions on revenue growth, profit margins, and future P/E multiples in light of recent price target increases from DKK 226 to DKK 258 at Deutsche Bank and from DKK 210 to DKK 290 at Morgan Stanley. Analyst Commentary Recent research on Demant points to a more constructive tone, with several bullish analysts revisiting their assumptions on the stock and adjusting price targets to reflect updated views on growth potential and valuation.
NOVO B
DKK 322.25
Novo Nordisk
7D
-1.4%
1Y
-26.6%
CHEMM
DKK 409.80
ChemoMetec
7D
0.6%
1Y
-23.8%
AMBU B
DKK 68.60
Ambu
7D
2.9%
1Y
-28.7%
Narrative Update • Jul 01

AMBU B: Rising Competition Will Weigh On Future Share Performance

The analyst price target for Ambu has been reduced from DKK 78 to DKK 58, with analysts citing a more cautious near term outlook and rising competition as key reasons for the change. Analyst Commentary Recent commentary on Ambu reflects a more cautious tone, with bearish analysts flagging concerns around the company’s ability to deliver against expectations as competition increases.
COLO B
DKK 401.00
Coloplast
7D
1.5%
1Y
-33.2%
Narrative Update • Jun 30

COLO B: Reset Expectations And New Products Will Shape Future Sentiment

The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
BAVA
DKK 183.50
Bavarian Nordic
7D
-3.7%
1Y
1.5%
ALK B
DKK 242.60
ALK-Abelló
7D
-0.6%
1Y
24.7%
Narrative Update • Jun 26

ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership

Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
HLUN B
DKK 42.48
H. Lundbeck
7D
-1.5%
1Y
22.0%
GUBRA
DKK 355.60
Gubra
7D
8.4%
1Y
-14.3%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
BIOPOR
DKK 1.07
BioPorto
7D
-5.8%
1Y
-23.9%